Duke Street Bio Ltd.

Duke Street Bio Receives EMA Approval for First-in-Human Trial of PARP1 Inhibitor DSB2455

8 months ago

• Duke Street Bio has been granted EMA approval to begin a clinical trial for DSB2455, a highly-selective PARP1 inhibitor. • DSB2455 targets cancers with homologous recombination deficiencies, including BRCA mutations, potentially improving treatment outcomes. • Preclinical data suggests DSB2455 has a strong safety profile and compelling efficacy, offering a potential advancement in cancer treatment. • The trial aims to address the unmet medical need in patient populations where first-generation PARP inhibitors have limitations.